Device Trial Radar · NCT07806409
Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2027
Study completion Jun 2032
Sponsor
- Lead sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.
Conditions
- Aortic Stenosis
- Aortic Valve Stenosis
- Severe Aortic Stenosis
Interventions
INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart ValveDevice
Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device Success According to VARC-3 CriteriaTime frame: 30 days after the procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.